Patent information
IP India · live recordAbstract
The invention provides a prolonged release pharmaceutical composition of Indapamide comprising 0.1-2%) w/w of Indapamide, 10-25%) w/w of one or more cellulose derivatives polymers with the viscosity of 20-80 cP measured using 0.5% w/w of aqueous solution. The prolonged release pharmaceutical composition of Indapamide provides the drug release upto 24 hour, useful in the treatment of hypertension.
Applicants
1Inventors
2Claims
7Specification
Show full textCollapse
FIELD OF THE INVENTION The invention provides a prolonged release pharmaceutical composition of Indapamide comprising one or more cellulose derivatives polymers selected from hydroxy propyl methyl cellulose (HPMC) or sodium carboxy methyl cellulose or both. The invention also provides a prolonged release pharmaceutical composition of Indapamide and processes for preparation thereof. BACKGROUND OF THE INVENTION Indapamide is chemically known as 3-(Aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-lH-indol-l-yl)benzamide and its chemical structure is as follows: Ov NH2 Indapamide is a diuretic antihypertensive agent which involves the renal and extrarenal actions exerts its mechanism of action in the control of hypertension. The site of action from renal is proximal part of the distal tubule and the ascending part of Henle's loop where Sodium and chloride ions are excreted in approximately equivalent amounts. The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion and hypokalemia. Indapamide is a 2-methyl indoline derivative of 4-chloro-3-sulfamoyl benzamide. It is referred to as a thiazide-like diuretic as its action is similar to the thiazide diuretics. It inhibits sodium and chloride reabsorption from the distal convoluted tubule by blocking the sodium/chloride co-transporter (symporter). Dose based response have shown that Indapamide lowers blood pressure (BP) at doses below that needed to elicit a diuresis, and appears to have antihypertensive effects other than diuresis. Indapamide is rapidly absorbed from the gastrointestinal tract and peak plasma concentrations are seen 1-2 hours after dosing. Because of its long half-life, it is effective in once daily dosing. Indapamide is extensively metabolised, with only about 7% of the total dose administered recovered in the urine as unchanged drug during the first 48 hours after administration. It is pharmaceutically compatible with most of the reported adjuvants/excipients. The target population with uptake the dose of Indapamide is delivered to age group more than 18 to get desired response. Targeted population to get affect from hypertension mainly ranges more than 18 and in most of cases age range between 35-50 having the high blood pressure. For this age range there is a need to minimise the dosing frequency to have a less dependency on multiple dosing and also minimise the side effects. Indapamide was approved in India by Central Drugs Standard Control Organisation on Jun 12, 1996 as sustained release coated tablet for the treatment of moderate hypertension. The registered brand name available for Indapamide as NATRILIX SR sold by Servier Laboratories. Indapamide as new amino indoline derivatives compounds were disclosed in GB 1,203,691 (Science Union, Laszlo Beregi Pierre et al.,1969) Pierre et al in this disclosed the diuretic and anti-hypertensive properties of various amino indoline compounds and their method of preparation using n-amino indoline as starting material. Compound preparation is disclosed. The composition disclosed by Alain Cuine et al in EP0519820 (1992) as matrix tablets for sustained release of Indapamide. Natrilix® marketed tablets of Indapamide were launched at Australia on December 1998 by Servier Laboratories. The sustained release is controlled by the use of specific viscosity between 1000 to 20,000 centipoise of methylhydroxypropyl cellulose and 10,000 to 7,00,000 centipoise (cP) of polyvidone. The process for preparation of the tablet includes a wet granulation step wherein the Indapamide, polyvidone and lactose are combined with an aqueous-alcoholic granulation liquid to yield granules, which are then dried and mixed with the methylhydroxypropyl cellulose. Finally, lubricant is added and the mixture is compressed to prepare the tablets. Josse R. Thomas et al in Suppl II Hypertension, Vol 7, No 6, Nov 1985 discloses the dose of 2.5mg of Indapamide once daily effectively reduces arterial blood pressure in about two-thirds of patients with mild to moderate hypertension and that this reduction is related to the severity of the hypertension. The dose depended frequency is showing less side effects and a simple once-daily dosage regimen. However, the dose dependent side effects during 2.5mg have been reported. Specifically, Hypokalaemia reported in patient history of taking such dose of2.5mg. Katarzyna Jureczek et al in WO2004/002475 (2002) discloses the tablets preparation process first mixing the Indapamide with lactose monohydrate and copovidone. Then the mixture is moistened with purified water and then granulated. The granulate thus obtained is dried, cooled, mixed with hypromellose having the viscosity ranges between 1000 to 20,000 cP and lubricants and compressed in a tabletting machine.Andrejka Kramar et al in WO2005/074884 (2005) discloses a sustained release pharmaceutical composition of Indapamide in the form of a tablet obtainable through the direct compression process using oligosaccharide or polysaccharide with cellulose derivative with the viscosity of 1000 to 15000cps as hydrophilic matrix former. MireilleDebauge etalm EP1902709 (2005) and EP1669062 (2005) teaches that it is not necessary to combine two polymers from two different chemical families in order to achieve extended release of Indapamide from tablets. The disclosed invention does not contain povidone but a mixture of 20 to 50% by weight of a medium (4000 cP) or high viscosity polymer (15,000 and 100,000 cP.), and from 0.5 to 10% by weight and of a low viscosity polymer (05 cP ), in combination used to control the sustained release. The mixture of medium high and low viscosity cause the dual mechanism in single tablet which results in not achieve the initial 50%) release within desired time. The release of the active ingredient is both diffusion and erosion of the matrix, cause the initial release more than 50% in first 3 hours. Hence still a need remain to prepare the composition which capable to maintain the linear release profile of initial 08 hours. However, the described prior art processes result in composition with Indapamide showing high fluctuations in terms of their drug content, release profile and desired time interval for drug release which for pharmaceutical preparations administering active ingredients to the human body is highly undesirable. Still need remain to obtain a better therapeutic index at lower expenditure and to prepare such a composition which is capable to deliver the drug as prolonged period of time in order to produce medication for safe and economical manner. The dosing frequency is also a motivation to formulate such a composition which can reduce the dosing frequency and able to provide the optimum onset of action. Thus, there exists unmet need to provide a composition, which is simple, stable and easy to manufacture and at the same time provides a steady state plasma concentration of drug and the composition is scalable on industrial scale with enhance release profile capable to follow the linear release profile upto initial 08 hours. Formulations described in prior art with the sustained release pattern also not capable to follow the linear release profile upto initial 08 hours. Inventors of the present invention observed contrary to the teaching of prior art that it was not necessary to combine two polymers of different category, namely a high viscosity HPMC and povidone or two HPMC grades with different viscosities for release of the active prolonged release principle. Inventors of the present invention optimised the ratio of HPMC of viscosity less than 100 cP with salts of polycarboxymethyl as polymer mixture of cellulose derivative polymers to meet the desired linear release profile. There is a further need to optimize the extended release pharmaceutical dosage forms comprising Indapamide, affective for 24 hours with precise delivery of drug to minimise the dose dependency and in order to make it convenient to manufacture, administer, and provide the requisite daily dosage of Indapamide. SUMMARY OF THE INVENTION The present invention relates to prolonged release pharmaceutical composition of Indapamide with cellulose derivatives polymer as an excipient. In one aspect of present invention, it relates to a prolonged release pharmaceutical composition of Indapamide comprising 0.1-2% w/w of Indapamide, 10-25%) w/w of one or more cellulose derivatives polymers with the viscosity of ranging between 20-80 cP measured using 0.5% w/w of aqueous solution. In another aspect of present invention, it relates a prolonged release pharmaceutical composition, wherein the said composition provides drug release upto 24 hours. It yet another aspect of present invention it relates to a process of preparing prolonged release pharmaceutical composition of Indapamide, wherein the process comprises the steps of: a) sifting filler, Indapamide and lubricants b) dry mixing about l/4th amount of filler with Indapamide c) blending the remaining quantity of filler with step b) drug mixture in blender. d) adding cellulose derivate polymers with glidant and blending for 5-15 min. e) blended material of step d) wetted using aqueous media and mixed in RMG for 10-3 Omin. f) granulating the material of step e) in RMG using impeller rotation of 80- 120 rpm & chopper speed at 2500 to 3000 rpm for less than 2 min. g) drying the granules for 15-20 min at 50-60°C and sifting, h) dried the granules after sifting at 50-70 °C. i) adding cellulose derivate polymers mixed for 5-15 min with blended material after pass through #30-#50 sieve, j) lubricating the mixing material for time ranging between 5 to 60 min after sieving. k) compressing or encapsulating the lubricated material and optionally performing aqueous coating. A prolonged release pharmaceutical composition of Indapamide according to the present invention can provide up to 24-hour release profile, which may be useful for the treatment of hypertension. Various other specific aspects of the invention are further detailed in the description part of the specification, wherever appropriate. DETAILED DESCRIPTION OF THE INVENTION The present invention provides prolonged release pharmaceutical composition of Indapamide with other suitable excipients which may be used for the treatment of hypertension. In one embodiment according to the present invention, it provides the prolonged release pharmaceutical composition of Indapamide comprising 0.1-2% w/w of indapamide, 10-25% w/w of one or more cellulose derivatives polymers with the viscosity of 20-80 cP measured using 0.5% w/w of aqueous solution. The term "Indapamide" as used herein, includes the compound Indapamide, pharmaceutically acceptable salts, esters and prodrugs thereof, the active metabolites of imatinib, and any of their polymorphs, solvates, hydrates. Formulations can contain Indapamide in the range of 1 to 2.5 mg per dosage unit. The release pattern of pharmaceutical composition of the present invention may be in the form of "prolonged release" or "immediate release" or "extended release" or "modified-release" or "sustained-release" or "delayed-released" or "pulsatile-release". The inventors of the present invention utilize the advantages of drug property and formulate a composition with such a release pattern which is capable to maintain the therapeutic blood or tissue levels of the drug for prolonged period of time. The pharmaceutical composition of the present invention may be in the form of oral solid dosage form preferably tablet, capsule, powder, granules, prolonged release, sustained release, control release, immediate release composition. The inventors of the present invention came up with the solution as oral solid composition in the form of prolonged release profile, which is patient compliance and easy to intake as per lowering the dosing frequency. The cellulose polymer substances are selected from, but not limited to one or more of cellulosic polymers copolymers or its derivatives including ester cellulose, ether cellulose, nitrocellulose, methyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose; polyacrylates, methyl acrylates, cellulose acetate phthalate. The release of cellulose polymer is controlled by polymer viscosity and concentration. Chemistry of cellulose polymer encourages a strong, tight gel formation compared to other polymer. The cellulose polymer of different grades with different in viscosity have selected to optimise the polymer mixture. The present invention focusing on the aim to provide 0-8hrs zero order kinetics (linear release profile upto initial 8 hrs), more than 50% drug should be release in 12 hrs and more than 70% drug should be release in 24 hrs. It was observed by the inventor of the present application that high viscosity cellulose polymer more than 2000 cP provides the release within 12-15 hours, cellulose polymer mixture (HPMC+CMC) with lower viscosity (20 cp in 0.5% concentration and 50 rpm with 62 spindle) results in loose matrix formation and 100%) drug release less than 12 hrs which was not found suitable for desired release profile. Cellulose polymer mixture (HPMC+CMC) with higher viscosity (4000 cP in 0.5%) cone, with 61 spindle 50 rpm) results in strong matrix formation and observed drug release not more than 60%> upto 24 hrs which was also not found satisfactory to provide desired release profile. To control the release up to 24 hours, inventors surprisingly found that cellulose polymers of less than 100 cP and sodium salt of polycarboxymethyl as second cellulose derivative have shown encouraging results as polymer mixture for providing constant release of a drug. The optimised mixture of cellulose derivative polymer having viscosity less than 100 cP with sodium salt of polycarboxymethyl in the ranges between 10-50%, particularly 10-30% results in follows the zero-order release profile. The optimised mixture surprisingly provided the required linear release profile and inventors of the present invention found the interactions between ionized drug molecules and polar groups on the polycarboxymethyl as (sodium CMC) are major attributable to the rate of swelling and desired rate of erosion. According to the present invention prolonged release pharmaceutical composition of Indapamide with one or more cellulose derivatives polymers thereof is provided. Employing modified drug release assays it has surprisingly been found that the use of particular cellulose derivatives polymer mixture having a certain optimum viscosity, notably below 100 cP. (determined according to USP35<912> Rotational rheometer methods at 20°C) enables robust prolonged release from the pharmaceutical composition under mechanical and chemical stress conditions as encountered in the gastrointestinal tract. Under physiological conditions an orally administrated dosage form undergoes considerable mechanical stress during its passage through the gastrointestinal tract, in particular during transition through the pylorus. In specific embodiment cellulose polymer is selected from hydroxypropyl methylcellulose having the viscosity less than 100 cP of 0.5% solution and polycarboxymethyl polymer as sodium carboxymethylcellulose or mixture of both. The term "prolonged-release ", as used herein, can be used synonymously with "extended release" or "modified-release" or "sustained-release" or "delayedreleased" or "pulsatile-release" based on the type of release required and is understood to mean a drug dosage system in which the rate of the API release is more precisely controlled and is delivered from the dosage system at a predictable and predetermined rate within the body of a patient such that a therapeutically effective blood level, devoid of peak and trough fluctuations, over an extended period of time. This definition excludes "immediate release" oral pharmaceutical dosage forms, which consist of pharmaceutical dosage forms which release the active drug immediately after oral administration. In another embodiment according to the present invention, it provides the process of preparing prolonged release pharmaceutical composition of Indapamide wherein the process comprises the steps of: a) sifting filler, Indapamide and lubricants b) dry mixing about l/4th amount of filler with Indapamide c) blending the remaining quantity of filler with step b) drug mixture in blender. d) adding cellulose derivate polymers with glidant and blending for 5-15 min. e) blended material of step d) wetted using aqueous media and mixed in RMG for 10-3 Omin. f) granulating the material of step e) in RMG using impeller rotation of 80- 120 rpm & chopper speed at 2500 to 3000 rpm for less than 2 min. g) drying the granules for 15-20 min at 50-60°C and sifting. h) dried the granules after sifting at 50-70 °C. i) adding cellulose derivate polymers mixed for 5-15 min with blended material after pass through #30-#50 sieve. j) lubricating the mixing material for time ranging between 5 to 60 min after sieving. k) compressing or encapsulating the lubricated material and optionally performing aqueous coating. The step a) of sifting the filler, Indapamide and lubricant according to the present invention, carried out in a shifter by conventional method using mesh size ranges between #50 to 70#, however it was optimised by the inventors of the present invention that sifting of excipients and Active Pharmaceutical Ingredient before mixing gives uniformity and promote the powder flow. Furthermore, the step b) of dry mixing the sifted material with Vi amount of filler with Indapamide by manually mixing. The mixing was performed at the temperature ranges 30-40°C for a time period of 15 min. The step c) of blended the mixed material of step b) in an octagonal blender with remaining amount of filler and blend for 15-30 min at 20-30 rpm. The dried mixing of filler using different amount at different stage provides advantage with material handling and powder better flow of powder. The step d) of adding cellulose derivative polymer in to the blender with lubricant and blended for 05-15 min at 15-30 rpm. The step of adding cellulose derivative polymer and lubricant performed as part of dry mixing in blender. The inventors of the present invention found the advantage of blending polymer with small amount of lubricant using dry mixing as impact on material handling. Further granulation process of step e) carried out by slowly wetted the dry mixed blend material of step d) using warm aqueous media of 45-50°C in RMG and slowly mixed for 15-30 min. Addition of slowly aqueous media with slowly mixing in RMG helpful to wet the mass properly before shearing. Granulating the wetted mass in step f) in RMG using impeller rotation of 80-120rpm and slow down to 40-60 rpm and set the chopper at 2500-3000 rpm for less than 02 min. Inventors have found this process of granulation at said rpm to be most effective rotation ranges to prepare the granules of desired uniformity size range. Drying the prepared granules in step g) of present invention as semi-drying using air temperature of 50-60°C for 10-20 min and sifting the granules using 5- 10# mesh size to get the uniform granules in semi-dried form. Drying the semi-dried granules in step h) at the temperature ranges between 55-75°C for the to achieve the LOD (<2%). Shifting the dried granules using 20- 30# mesh size to get the uniform granules. Adding remain cellulose derivative polymer as in step i) of the present invention and mixing for 5-15 min in Octagonal blender after sifted with 30-50# mesh size. Inventors surprisingly observe the better intact property of composition and improvement in release profile when Cellulose polymers are distributed in different ratio. The addition of different ratio at different steps for preparation for composition enhance the release profile for prolonged period of time. Lubrication as per step j) of sifting the Magnesium stearate and colloidal anhydrous silica using the size ranges between 50-70# and adding in blended material as step i) by mixing for 5-10 min. The step k) of present invention processed for lubricated mass for compression and/or encapsulating in capsules shell followed by optional aqueous coating. In a particular embodiment of the present invention, it provides to prepare prolonged release pharmaceutical compositions of Indapamide comprising 78.5- 83.6% of lactose, 8.75-12.47% of hydroxypropyl methyl cellulose, 3.35-4.34% of sodium carboxymethyl cellulose, 0.55% of aerosil. A prolonged release pharmaceutical composition of Indapamide described herein can further contain one or more fillers. In general, filler is a substance increasing the bulk volume of mixture and thus the size of final dosage form. Preferred examples of fillers are microcrystalline cellulose, powdered cellulose, lactose (anhydrous or monohydrate), starch (e.g., corn starch or potato starch), pregelatinized starch, sugar and sugar alcohol like mannitol, fructose, sucrose, dextrose, xylitol, dextrans, sorbitol, saccharose, calcium hydrogen phosphate, calcium hydrogen phosphate dihydrate, dicalciumphosphatedihydrate, tricalciumphophate, or mixtures thereof. The preferred filler is lactose. Lubricants ensure that tablet formation and ejection can occur with low friction between the dosage forms (solid) and die wall. Preferred examples of lubricants are Sodium Stearyl Fumarate (SSF), Sucrose stearate, magnesium stearate, stearic acid, calcium stearate, hydrogenated vegetable oil, hydrogenated castor oil, macrogols, glycerylbehenate, talc, silicone dioxide or mixtures thereof. The preferred lubricant is magnesium stearate. It has been observed by present inventors that various composition discussed in prior art suffer a disadvantage of multiple dependency of dose either less dissolution profile or not meeting the release for desired period of time. The present invention provides economical aqueous coating as an advantage over nonuniform and difficult which may results as blistering, chipping, picking, blushing, cracking (splitting) or the like. The term "oral" administration means that the active agent is in a formulation designed to be ingested, i.e. designed to be delivered to the gastrointestinal system for absorption. The term "prolonged release" or "pharmaceutical composition" comprises capsule, tablet (film coated tablet, controlled release tablet, modified release tablet, extended release, delayed release, immediate release etc.), micro tablet, powder, granule and pellets. Capsules used as oral dosage form can be soft or hard capsules, though oral dosage form of the present invention is tablet or capsule. The term "about" is a value that can be considered ±5% of the given value. Based on context of discussion, the term "% w/w" refers to the relative value to total weight of granules or to total weight of pharmaceutical composition and "%v/v" refer to volume by total volume percentage. In one of embodiments, the application provides pharmaceutical dosage forms of otilonium bromide having content uniformities (CU) from about 90% to about 110% by weight, with relative standard deviations (RSD) of not more than about 5%. In embodiments, the invention provides to pharmaceutical formulations having friability not more than about 1 % w/w. Usage of the terms "a" and "an" and "the" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising" "having" "including" and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to") unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The term wt% refers to percent by weight. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples or exemplary language (e.g. "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention. The terms "excipients", "adjuvant", "pharmaceutically acceptable excipients" and "pharmaceutically compatible excipients", are used interchangeably in this disclosure. They refer to non-API substances such as disintegrators, binders, fillers, and lubricants used in formulating pharmaceutical composition. They are generally safe for administering to humans according to established governmental standards, including those promulgated by the United States Food and Drug Administration. Particular embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those particular embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in best possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context. While the forgoing pages provide a detailed description of the preferred embodiments of the invention, it is being understood that the summary and description are illustrative only of the core of the invention and non-limiting in scope. Furthermore, as many changes can be made to the invention without departing from the scope of the invention, it is intended that all material contained herein be interpreted as illustrative of the invention and not in a limiting sense. Table 01 Example 01-03 Preparation of Prolonged Release Tablet using wet granulation: S.No. 1. 2. Ingredients Name Quantity per tablet (mg) Example 01 Example 02 Dry Mixing/Intragranular Indapamide BP* Lactose BP** 1.5 161.50 1.5 171.5 Example 03 1.5 164.5 3. 4. 5. 6. 7. 8. 9. 10. HPMC Aerosil Sodium CMC Extragranular HPMC Sodium CMC Magnesium stearate BP Aerosil BP Coating Opadry03F180011 Average Weight 10.35 0.15 4.5 15.6 4.4 1.0 1.0 5 205 7.35 0.15 3.5 10.6 3.4 1.0 1.0 205 9.35 0.15 4.5 13.6 4.4 1.0 1.0 205 Manufacturing process for preparation of Indapamide prolonged release tablet composition using wet granulation: a) sifting filler, lubricants and Indapamide using sieve size ranges from #40 to #70 b) dry mixing of 1/4th amount of filler with Indapamide for 10 to 20 min. c) blending the remaining quantity of filler with Indapamide for 15 to 30 min at 20-30 rpm. d) adding cellulose derivate polymers with glidant and blending for 5-15 min at 20-30 rpm e) blended material of step d) wetted using aqueous media and mixed in RMG for 10-30min. f) granulating the material of step e) in RMG using impeller rotation of 80- 120 rpm & chopper speed at 2500 to 3000 rpm for less than 2 min. g) drying the granules for 40-70 min at 45-65°C and sifting by using #5 to #15 sieve. h) blending the dried granules after sifted through #20 to #30 i) adding cellulose derivate polymers mixed for 5-15 min with blended material after pass through #30-#50 sieve. j) lubricating the mixing material for 15 min after sieving with #40-#60 mesh size. k) compressing or capsulate the lubricated mass and optionally aqueous coating. Table 02 Example 04 Preparation of Prolonged Release Tablet using direct compression: S.No. 1. 2. 3. 4. 5. Ingredients Name Indapamide BP Lactose BP Hydroxypropyl methyl cellulose- K15M Magnesium stearate BP Aerosil BP AvgWt Qty mg/tab 1.5 154.45 42 1.00 1.00 200.00 Manufacturing process for preparation of Indapamide prolonged release tablet composition using direct compression: 1. Indapamide passed through # 40-50 sieve no. 2. lactose passed through #40-50 sieve no. and add in step-1 (with geometrically mixing), 3. Then hydroxypropyl methyl cellulose-K15M passed through #40-50 sieve no. and add in step-1, 4. Transfer blend in blender and mixed for 30-40 minutes at 22-30 RPM. 5. magnesium stearate and aerosil passing through #60-70 sieve no. add in whole blend and mix for 5-10 minutes in blender. 6. The blended mass is compressed using suitable punch size. Tablets prepared of Examples is packaged in closed Alu/Alu Blister or PVC/Alu Blister and stored at three different conditions: 25°C and 60%> relative humidity (Condition 1), 30°C and 65% RH (Condition 2) or 40°C and 75% RH (Condition 3) for one month. Dissolution testing results of initial and stored samples are shown in Table 3. The dissolution study is conducted in 900 ml of 6.5 pH phosphate buffer using basket apparatus, while stirred at 100 rpm for 24 hours. The temperature of the dissolution medium was maintained at 37 ± 0.5 °C. Dissolution testing results of marketed tablet and Examples 01-03 are shown in Table 03: TABLE 03 Time (hours) 0 1 2 4 8 12 24 Cumulative % Drug Dissolved Trial 01 Avg. 0 7 13 25 51 68 99 %RSD 0 0.52 0.75 0.63 5.09 6.98 7.19 Trial 02 Avg. 0 12 19 37 70 91 98 %RSD 0 0.55 0.82 2.94 3.15 3.87 5.23 Trial 03 Avg. 0 9 15 29 60 80 95 %RSD 0 0.82 0.52 1.17 11.62 14.68 9.77 Natrilix SR Avg. 0 4 9 22 42 63 98 %RSD 0 0.42 0.62 1.1 4.2 5.7 8.9 The abovementioned examples, which are provided by way of illustration, should not be construed as limiting the scope of the invention with respect to parameters, ingredients and quantities used in any manner.
We Claim: 1. A prolonged release pharmaceutical composition of Indapamide comprising 0.1-2% w/w of Indapamide, 10-25% w/w of one or more cellulose derivatives polymers with the viscosity of 20-80 cP measured using 0.5% w/w of aqueous solution. 2. A prolonged release pharmaceutical composition prepared according to claim 1, wherein the said prolonged release composition provides drug release upto 24 hours. 3. A prolonged release pharmaceutical composition according to claim 1, wherein one or more cellulose derivative polymers are selected from hydroxy propyl methyl cellulose (HPMC) or sodium carboxy methyl cellulose or both present in a ratio of about 1:3. 4. A process of preparing prolonged release pharmaceutical composition of Indapamide, wherein the process comprises the steps of: a) sifting filler, Indapamide and lubricants b) dry mixing about l/4th amount of filler with Indapamide c) blending the remaining quantity of filler with step b) drug mixture in blender. d) adding cellulose derivate polymers with glidant and blending for 5-15 min. e) blended material of step d) wetted using aqueous media and mixed in RMG for 10-3 Omin. f) granulating the material of step e) in RMG using impeller rotation of 80- 120 rpm & chopper speed at 2500 to 3000 rpm for less than 2 min. g) drying the granules for 15-20 min at 50-60°C and sifting, h) dried the granules after sifting at 50-70 °C. i) adding cellulose derivate polymers mixed for 5-15 min with blended material after pass through #30-#50 sieve. j) lubricating the mixing material for time ranging between 5 to 60 min after sieving, k) compressing or encapsulating the lubricated material and optionally performing aqueous coating. 5. A prolonged release pharmaceutical composition prepared according to claim 4 wherein filler used in said composition selected from lactose, xylitol or mannitol. 6. A prolonged release pharmaceutical composition prepared according to claim 4 wherein glidant used in said composition are selected from colloidal anhydrous silica, talc or starch. 7. A prolonged release pharmaceutical composition prepared according to claim 4 may be used for the treatment of hypertension.